An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design
- Kobat, Mehmet Ali
- Zengin, Halit
- Gunduz, Mahmut
- TUNÇEZ, ABDULLAH
- KARAVELİOĞLU, YUSUF
- Gokdeniz, Tayyar
- KOZA, Yavuzer
- Aktop, Ziyaeddin
- Katlandur, Huseyin
- KARACA ÖZER, Pelin
- YÜKSEL, MURAT
- ACET, HALİT
- ÇİL, HABİB
- Alan, Sait
- Ertas, Faruk
- KAYA, HASAN
- YILDIZ, ABDULKADİR
- Davutoglu, Vedat
- Kiris, Abdulkadir
- Dinc, Lale
- Kafes, Habibe
- Avci, Anil
- ÇALAPKORUR, Bekir
- Ertas, Gokhan
- Gul, Mehmet
- KAHRAMAN AY, NURAY
- Bulur, Serkan
- Durukan, Mine
- Eren, Murat
- Ilhan, Ibrahim
- TOPRAK, NİZAMETTİN
- KÜÇÜK, MURATHAN
- ÖZPELİT, EBRU
- Şimşek, Hakkı
- Ucar, F. Mehmet
- Yildiz, Ahmet
- Sahin, D. Yildiray
- Ayhan, Erkan
- Caglayan, C. Emre
- GÜNGÖR, HASAN
- Ozyurtlu, Ferhat
- Sen, Nihat
- Vatan, Bulent
- Vatansever, Fahriye
- Temiz, Ahmet
- TAYLAN, GÖKAY
- Donmez, Ibrahim
- Erkus, M. Emre
- Soylemez, Selami
DOIAbstract
Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients
Add to ORKG